Interleukin-1 function and role in rheumatic disease

Nature Reviews Rheumatology

Volumn 12, Issue 1, 2016, Pages 14-24

  Schett, Georg ^a   Dayer, Jean Michel ^b   Manger, Bernhard ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; GEVOKIZUMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1BETA; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTHROPATHY; BEHCET DISEASE; BONE LESION; CARDIOVASCULAR DISEASE; CINCA SYNDROME; CRYSTAL INDUCED ARTHROPATHY; CYTOKINE PRODUCTION; DEFICIENCY IN INTERLEUKIN 1 RECEPTOR ANTAGONIST; DRUG EFFICACY; FAMILIAL MEDITERRANEAN FEVER; GOUT; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; OSTEOMYELITIS; PAPA SYNDROME; PATHOGENICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PSEUDOGOUT; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SAPHO SYNDROME; SCHNITZLER SYNDROME; SIGNAL TRANSDUCTION; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; IMMUNOLOGY; INNATE IMMUNITY; MAST CELL; METABOLISM;

HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1; MAST CELLS; RHEUMATIC DISEASES;

EID: 84954198098     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2016.166     Document Type: Review

References (147)

1. Dinarello, C. A., Renfer, L. & Wolff, S. M. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc. Natl Acad. Sci. USA 74, 4624-4627 (1977).
2. Lomedico, P. T. et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature. 312, 458-462 (1984).
3. Auron, P. E. et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl Acad. Sci. USA 81, 7907-7911 (1984).
4. Gery, I. & Waksman, B. H. Potentiation of the T-lymphocyte response to mitogens. J. Exp. Med. 136,143-155 (1972).
5. Dinarello, C. A., Goldin, N. P. & Wolff, S, M. Demonstration and characterization of two distinct human leukocytic pyrogens. J. Exp. Med. 139, 1269-1281 (1974).
6. Dinarello, C. A. & Bernheim, H. A. Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro. J. Neurochem. 37, 702-708 (1981).
7. Dayer, J. M., Robinson, D. R & Krane, S. M. Prostaglandin production by rheumatoid synovial cells: stimulation by a factor from human mononuclear cells. J. Exp. Med. 145, 1399-1404 (1977).
8. Horton, J. E. et al. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science 177, 793-795 (1972).
9. Dayer, J. M., Graham, R., Russell, G. & Krane, S. M. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 195, 181-183 (1977).
10. Saklatvala, J. & Dingle, J. T. Identification of catabolin, a protein from synovium which induces degradation of cartilage in organ culture. Biochem. Biophys. Res. Commun. 16, 1225-1231 (1980).
11. Mizel, S. B, Dayer, J.-M., Krane, S. M. & Mergenhagen, S. E. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc. Natl Acad. Sci. USA 78, 2474-2477 (1981).
12. Baracos, V., Rodemann, H. P., Dinarello, C. A. & Goldberg, A. L. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1)-a mechanism for the increased degradation of muscle proteins during fever. N. Engl. J. Med. 10, 553-558 (1983).
13. Aarden, L. A. et al. Revised nomenclature for antigen nonspecific T cell proliferation and helper factors. J. Immunol. 123, 2928-2929 (1979).
14. Netea, M. G., van de Veerdonk, F. L., van der Meer, J. W., Dinarello, C. A. & Joosten, L. A. Inflammasome-independent regulation of IL-1-family cytokines. Annu. Rev. Immunol. 33, 49-77 (2015).
15. Dinnarello, C. et al. IL-1 family nomenclature. Nat. Immunol. 11, 973 (2010).
16. Garlanda, C., Dinarello, C. A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003-1018 (2013).
17. van de Veerdonk, F. L. et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl Acad. Sci. USA 109, 3001-3005 (2012).
18. Rudloff, I. et al. Interleukin 38 exerts anti-inflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.39328 (2015).
19. Wilson, K. P. et al. Structure and mechanism of interleukin-1 converting enzyme. Nature 370, 270-275 (1994).
20. Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1 processing in monocytes. Nature 356, 768-774 (1992).
21. Chen, C. J. et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13, 851-856 (2007).
22. Afonina, I. S., Mller, C., Martin, S. J. & Beyaert, R. Proteolytic processing of Interleukin-1 family cytokines: variations on a common theme. Immunity 42, 991-1004 (2015).
23. Schroder, K., Zhou, R. & Tschopp, J. The NLRP3 inflammasome: a sensor for metabolic danger Science 327, 296-300 (2010).
24. Netea, M. G. et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1 in monocytes and macrophages. Blood 113, 2324-2335 (2009).
25. Ferrari, D. et al. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176, 3877-3883 (2006).
26. Elssner, A. et al. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 processing and release. J. Immunol. 172, 4987-4994 (2004).
27. Karmakar, M. et al. Neutrophil IL-1 processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. J. Immunol.194, 1763-1775 (2015).
28. Chen, K. W. et al. The neutrophil NLRC4 inflammasome selectively promotes IL-1 maturation without pyroptosis during acute Salmonella challenge. Cell Rep. 8, 570-582 (2014).
29. Coeshott, C. et al. Converting enzyme-independent release of tumor necrosis factor and IL-1 from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc. Natl Acad. Sci. USA 96, 6261-6266 (1999).
30. Sugawara, S. et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. 167, 6568-6575 (2001).
31. Irmler, M. et al. Granzyme A is an interleukin 1-converting enzyme. J. Exp. Med. 181, 1917-1922 (1995).
32. Herzog, C. et al. Meprin A and meprin generate biologically functional IL-1 from pro-IL-1. Biochem. Biophys. Res. Commun. 379, 904-908 (2009).
33. Schauer, C. et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20, 511-517 (2014).
34. Rider, P. et al. IL-1 and IL-1 recruit different myeloid cells and promote different stages of sterile inflammation. J. Immunol. 187, 4835-4843 (2011).
35. Cohen, I. et al. Differential release of chromatin-bound IL-1 discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl Acad. Sci. USA 107, 2574-2579 (2010).
36. Seckinger, P. et al. A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J. Immunol. 139, 1541-1545 (1987).
37. Dinarello, C. A. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 343, 732-734 (2000).
38. Kuhn, P. H. et al. Regulated intramembrane proteolysis of the interleukin-1 receptor II by-,-, and-secretase. J. Biol. Chem. 282, 11982-11995 (2007).
39. Re, F. et al. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface 'receptor' with anti-interleukin-1 function. J. Exp. Med. 183, 1841-1850 (1996).
40. Colotta, F. et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 261, 472-475 (1993).
41. Burger, D., Chicheportiche, R., Giri, J. G. & Dayer, J. M. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J. Clin. Invest. 96, 38-41 (1995).
42. Spits, H. et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145-149 (2013).
43. Kim, H. Y. et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat. Med. 20, 54-61 (2014).
44. Sutton, C. et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203, 1685-1691 (2006).
45. Chung, Y. et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30, 576-587 (2009).
46. Acosta-Rodriguez, E. V. et al. Interleukin 1 and 6 but not transforming growth factor-are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942-949 (2007).
47. Zielinski, C. E. et al. Pathogen-induced human TH17 cells produce IFN-or IL-10 and are regulated by IL-1. Nature 484, 514-518 (2012).
48. Chizzolini, C. et al. Prostaglandin E2 (PGE2) synergistically with interleukin-23 (IL-23) favors human TH17 expansion. Blood 112, 3696-3703 (2008).
49. Chizzolini, C. & Brembilla, N. C. Prostaglandin E2: igniting the fire. Immunol. Cell Biol. 87, 510-511 (2009).
50. Sutton, C. E. et al. Interleukin-1 and IL-23 induce innate IL-17 production from T cells, amplifying Th17 responses and autoimmunity. Immunity 31, 331-341 (2009).
51. Cosmi, L. et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med. 205, 1903-1916 (2008).
52. Maggi, L. et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur. J. Immunol. 40, 2174-2181 (2010).
53. Dayer, J. M. & Burger, D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Netw. 5, 563-571 (1994).
54. Zwerina, J. et al. TNF-induced structural joint damage is mediated by IL-1. Proc. Natl Acad. Sci. USA 104, 11742-11747 (2007).
55. Dayer, J. M. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 18, 31-45 (2004).
56. Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. & Russell, R. G. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306, 378-380 (1983).
57. Wei, S., Kitaura, H., Zhou, P., Ross, F. P. & Teitelbaum, S. L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115, 282-290 (2005).
58. Ferreira, S. H., Lorenzetti, B. B., Bristow, A. F. & Poole, S. Interleukin-1 as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334, 698-700 (1988).
59. Blumberg, H. et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med. 204, 2603-2614 (2007).
60. Kullberg, B. J., van 't Wout, J. W. & van Furth, R. Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infect. Immun. 58, 3319-3324 (1990).
61. Ozren, N. et al. Distinct roles of TLR2 and the adaptor ASC in IL-1/IL-18 secretion in response to Listeria monocytogenes. J. Immunol. 176, 4337-4342 (2006).
62. Warren, S. E., Mao, D. P., Rodriguez, A. E., Miao, E. A. & Aderem, A. Multiple Nod-like receptors activate caspase 1 during Listeria monocytogenes infection. J. Immunol. 180, 7558-7564 (2008).
63. Lara-Tejero, M. et al. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J. Exp. Med. 203, 1407-1412 (2006).
64. Juffermans, N. P. et al. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J. Infect. Dis. 182, 902-908 (2000).
65. Nuki, G. et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 2838-2846 (2002).
66. Fisher, C. J. Jr et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271, 1836-1843 (1994).
67. Cavalli, G. & Dinarello, C. A. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) 12, 2134-2144 (2015).
68. Manger, B., Weiss, A., Weyand, C., Goronzy, J. & Stobo, J. D. T cell activation: differences required for IL 2 production by nonactivated and activated T cells. J. Immunol. 135, 3669-3673 (1985).
69. Stojanov, S. & Kastner, D. L. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr. Opin. Rheumatol. 17, 586-599 (2005).
70. Rynne, M., Maclean, C., Bybee, A., McDermott, M. F. & Emery, P. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann. Rheum. Dis. 65, 533-534 (2006).
71. Lovell, D. J., Bowyer, S. L. & Solinger, A. M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52, 1283-1286 (2005).
72. Goldbach-Mansky, R. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 inhibition. N. Engl. J. Med. 355, 581-592 (2006).
73. Hawkins, P. N., Lachmann, H. J., Aganna, E. & McDermott, M. F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50, 607-612 (2004).
74. Kuijk, L. M., Govers, A. M., Frenkel, J. & Hofhuis, W. J. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann. Rheum. Dis. 66, 1545-1546 (2007).
75. Lindor, N. M., Arsenault, T. M., Solomon, H., Seidman, C. E. & McEvoy, M. T. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin. Proc. 72, 611-615 (1997).
76. Brenner, M., Ruzicka, T., Plewig, G., Thomas, P. & Herzer, P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br. J. Dermatol. 161, 1199-1201 (2009).
77. Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426-2437 (2009).
78. Gattorno, M. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58, 1516-1520 (2008).
79. Cailliez, M. et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit Metab. Dis. 29, 763 (2006).
80. Schorn, C. et al. Sodium overload and water influx activate the NALP3 inflammasome. J. Biol. Chem. 286, 35-41 (2011).
81. Martinon, F., Ptrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
82. Schiltz, C. et al. Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum. 46, 1643-1650 (2002).
83. Joosten, L. A. et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1 production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237-3248 (2010).
84. So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007).
85. Ghosh, P., Cho, M., Rawat, G., Simkin, P. A. & Gardner, G. C. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res. (Hoboken) 65, 1381-1384 (2013).
86. Ottaviani, S. et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res. Ther. 15, R123 (2013).
87. Schumacher, H. R. Jr et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a Phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res. (Hoboken) 64, 1462-1470 (2012).
88. Mitha, E. et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, Phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 52, 1285-1292 (2013).
89. Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. 71, 1839-1848 (2012).
90. Couderc, M., Mathieu, S., Glace, B. & Soubrier, M. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine 79, 330-331 (2012).
91. Zufferey, P. & So, A. A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder. Ann. Rheum. Dis. 72, 465-467 (2013).
92. Prieur, A. M., Kaufmann, M. T., Griscelli, C. & Dayer, J. M. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 2, 1240-1242 (1987).
93. Fitzgerald, A. A., Leclercq, S. A., Yan, A., Homik, J. E. & Dinarello, C. A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52, 1794-1803 (2005).
94. Vasques Godinho, F. M., Parreira Santos, M. J. & Canas da Silva, J. Refractory adult onset Still's disease successfully treated with anakinra. Ann. Rheum. Dis. 64, 647-648 (2004).
95. Ortiz-Sanjuán, F. et al. Efficacy of anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 94, e1554 (2015).
96. Lequerré, T. et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302-308 (2008).
97. Gattorno, M. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 1505-1515 (2008).
98. Ohlsson, V. et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 47, 555-556 (2008).
99. Horai, R. et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191, 313-320 (2000).
100. Wood, D. D., Ihrie, E. J., Dinarello, C. A. & Cohen, P. L. Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum. 26, 975-983 (1983).
101. Koch, A. E. et al. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. Clin. Immunol. Immunopathol. 65, 23-29 (1992).
102. Firestein, G. S. et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J. Immunol. 149, 1054-1062 (1992).
103. Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van den Berg, W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF, anti-IL-1/, and IL-1Ra. Arthritis Rheum. 39, 797-809 (1996).
104. Zwerina, J. et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 50, 277-290 (2004).
105. Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196-2204 (1998).
106. Cohen, S. B. et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63, 1062-1068 (2004).
107. Cohen, S. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614-624 (2002).
108. Dayer, J. M. et al. Anti-interleukin-1 therapy in rheumatic diseases. Curr. Opin. Rheumatol. 13, 170-176 (2001).
109. Jiang, Y. et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001-1009 (2000).
110. Rau, R., Sander, O. & Wassenberg, S. Erosion healing in rheumatoid arthritis after anakinra treatment. Ann. Rheum. Dis. 62, 671-673 (2003).
111. Bresnihan, B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 30, 17-20 (2001).
112. Alten, R. et al. Efficacy and safety of the human anti-IL-1 monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet. Disord.12, 153 (2011).
113. Mengshol, J. A. et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase and nuclear factor B: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 43, 801-811 (2000).
114. Kusano, K. et al. Regulation of matrix metalloproteinases (MMP-2,-3,-9, and-13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 139, 1338-1345 (1998).
115. Goldring, M. B. et al. Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J. Clin. Invest. 94, 2307-2316 (1994).
116. Tyler, J. A. Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochem. J. 227, 869-878 (1985).
117. Verbruggen, G. et al. Influence of human recombinant interleukin-1 beta on human articular cartilage. Mitotic activity and proteoglycan metabolism. Clin. Exp. Rheumatol. 9, 481-488 (1991).
118. Blanco, F. J. & Lotz, M. IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE2. Exp. Cell Res. 218, 319-325 (1995).
119. Attur, M. G. et al. Autocrine production of IL-1 by human osteoarthritis-affected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8. Proc. Assoc. Am. Physicians 110, 65-72 (1998).
120. Pelletier, J. P. et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 40, 1012-1019 (1997).
121. Fernandes, J. et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am. J. Pathol. 154, 1159-1169 (1999).
122. Chevalier, X. et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 61, 344-352 (2009).
123. Cohen, S. B. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13, R125 (2011).
124. Attur, M. et al. Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations. Ann. Rheum. Dis. 69, 856-861 (2010).
125. Kerkhof, H. J. et al. Large-scale meta-analysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritis. Osteoarthr. Cartil. 19, 265-271 (2011).
126. Heiland, G. R. et al. Synovial immunopathology in haemochromatosis arthropathy. Ann. Rheum. Dis. 69, 1214-1219 (2010).
127. Latourte, A., Frazier, A., Brire, C., Ea, H. K. & Richette, P. Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands. Ann. Rheum. Dis. 72, 783-784 (2013).
128. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 in type 2 diabetes. Nat. Immunol. 11, 897-904 (2010).
129. Hensen, J., Howard, C. P., Walter, V. & Thuren, T. Impact of interleukin-1 antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 39, 524-531 (2013).
130. Ridker, P. M. et al. Effects of interleukin-1 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a h IIb randomized, placebo-controlled trial. Circulation 126, 2739-2748 (2012).
131. Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597-605 (2011).
132. Roubille, F. et al. The interleukin-1 modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis 236, 277-285 (2014).
133. Krause, K. et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 67, 943-950 (2012).
134. De Koning, H. D. et al. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Ann. Rheum. Dis. 72, 1634-1638 (2013).
135. Lust, J. A. et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1-induced interleukin-6 production and the myeloma proliferative component. Mayo Clin. Proc. 84, 114-122 (2009).
136. Gl, A. et al. Interleukin-1-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann. Rheum. Dis. 71, 563-566 (2012).
137. Mansouri, B., Richards, L. & Menter, A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1 inhibitor gevokizumab. Br. J. Dermatol. 173, 239-241 (2015).
138. Pazyar, N., Feily, A. & Yaghoobi, R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr. Clin. Pharmacol. 7, 271-275 (2012).
139. Wendling, D., Prati, C. & Aubin, F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann. Rheum. Dis. 71, 1098-1100 (2012).
140. Rech, J. et al. Adult-onset Still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation. Rheumatol. Int. 32, 1827-1829 (2012).
141. Dinarello, C. A. & van der Meer, J. W. Treating inflammation by blocking interleukin-1 in humans. Semin. Immunol. 15, 469-484 (2013).
142. Coleman, K. M. et al. Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1, for the treatment of psoriasis. JAMA Dermatol. 151, 555-556 (2015).
143. Carter, D. B. et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 344, 633-638 (1990).
144. Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndroms: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443-2452 (2008).
145. Church, L. D. & McDermott, M. F. Rilonacept in cryopyrin-associated periodic syndroms: the beginning of longer-acting interleukin-1 antagonism. Nat. Clin. Pract. Rheumatol. 5, 14-15 (2009).
146. Chakraborty, A. et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1 monoclonal antibody. Clin. Pharmacokinet. 51, e1-e18 (2012).
147. Owyang, A. M. et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1-mediated diseases. MAbs 3, 49-60 (2011).